Wockhardt Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Smallcap 250 and 3.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Wockhardt reported a strong standalone quarter with revenue from operations rising to ₹413 crore from ₹352 crore a year ago (about 17% growth), while standalone profit after tax jumped to ₹69 crore from just ₹6 crore in Q1 FY25, lifting EPS to ₹4.25. On a consolidated basis, however, revenue was flat at ₹738 crore and the company slipped into a loss of ₹108 crore, largely due to a one-time ₹97 crore exceptional charge. The exceptional item relates to an impairment of goodwill after Wockhardt decided to exit the US generic pharmaceutical business, filing for voluntary liquidation of its US step-down subsidiaries Morton Grove Pharmaceuticals Inc and Wockhardt USA LLC under Chapter 7 of the US Bankruptcy Code on July 11, 2025. The statutory auditors (MSKC & Associates) issued an unmodified limited review report on both standalone and consolidated results.
Standalone numbers show a sharp earnings recovery, which is positive for shareholders, but the consolidated loss — driven by the US business shutdown and ₹97 crore impairment — highlights that the drag from the generics business had been significant. Investors should focus on the standalone turnaround while monitoring how cleanly the US exit is executed, as the Chapter 7 liquidation may continue to impact near-term consolidated optics.